GB1426042A - water-soluble immunological adjuvants - Google Patents

water-soluble immunological adjuvants

Info

Publication number
GB1426042A
GB1426042A GB5499371A GB5499371A GB1426042A GB 1426042 A GB1426042 A GB 1426042A GB 5499371 A GB5499371 A GB 5499371A GB 5499371 A GB5499371 A GB 5499371A GB 1426042 A GB1426042 A GB 1426042A
Authority
GB
United Kingdom
Prior art keywords
water
cells
cell wall
wall material
chloroform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB5499371A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bpifrance Financement SA
Original Assignee
Agence National de Valorisation de la Recherche ANVAR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agence National de Valorisation de la Recherche ANVAR filed Critical Agence National de Valorisation de la Recherche ANVAR
Priority to GB5499371A priority Critical patent/GB1426042A/en
Priority to GB2914973A priority patent/GB1440842A/en
Publication of GB1426042A publication Critical patent/GB1426042A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

1426042 Immunological agent AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE 26 Feb 1973 [26 Nov 1971] 54993/71 Heading A5B A water-soluble immunological agent is prepared by cultivating a strain of Mycobacteria or Nocardia, isolating the cultivated cells, disrupting the cells, isolating the ruptured cell wall material, removing lipids, protein and nucleic acids from the cell wall material, digesting the remaining material in a microlytic enzyme, removing any undigested solid residue and collecting the. aqueous fraction of the remainder. The product is characterized by containing 12-15% of amino, sugars, consisting of equimolar amounts of D-glucosamine and D-muramic acid; containing 12-15% of aminoacids consisting of L-alanine, D- alanine, D-glutamic acid and meso-alpha, betadiaminopimetic acid in the ratio 1:3:1:1; containing 60-70% of neutral sugars consisting of D-arabinose and D-galactose in the ratio 2:1; containing less than 5% of lipids, having an optical rotation [alpha]D in water of 11.3‹ Œ 0.5‹, having terminal ultraviolet absorption below 230 nm., having infra-red absorption at 1650, 1520 and 1000-1100 cm<-1>; and on lyophilization becoming white and fluffy, soluble in water to provide an opalescent solution, insoluble in ether, chloroform, acetone and mixtures of ethanol and chloroform. Bacteria strains specified include: Mycabacterium tuberculosis, variant hominis or bovis, Mycobacterium kansasii, Mycobacterium smegmatis, Calmette Guerin bacilli. In a preferred process, the cultivated cells may be suspended in water and disrupted in a French press or by ultrasonic vibrations. The ruptured cell wall material may be isolated by first centrifuging the disrupted cells first at low speed to precipitate any whole cells and then again at higher speed to precipitate the ruptured cell wall material. Lipids may be extracted with alcohol, acetone or chloroform, protein may be removed with trypsin or chymotrypsin and nucleic acids may be removed with desoxyribomnuclease. The murolytic enzyme may be lysozyme in the presence of a buffer agent. The final product may be repeatedly lyophilized and redissolved in water to remove the buffer. The final solution is filtered through a polydextran gel column.
GB5499371A 1971-11-19 1971-11-26 water-soluble immunological adjuvants Expired GB1426042A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB5499371A GB1426042A (en) 1971-11-26 1971-11-26 water-soluble immunological adjuvants
GB2914973A GB1440842A (en) 1971-11-19 1973-06-19 Immunological adjuvants and process for their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB5499371A GB1426042A (en) 1971-11-26 1971-11-26 water-soluble immunological adjuvants

Publications (1)

Publication Number Publication Date
GB1426042A true GB1426042A (en) 1976-02-25

Family

ID=10472651

Family Applications (1)

Application Number Title Priority Date Filing Date
GB5499371A Expired GB1426042A (en) 1971-11-19 1971-11-26 water-soluble immunological adjuvants

Country Status (1)

Country Link
GB (1) GB1426042A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52116416A (en) * 1976-03-10 1977-09-29 Anvar 22*22acetamidee22dioxyy33oodd glucopyranosyl**ddpropionyllllceryll ddisoglutamine or glutamic acid or adjuvants composed of mainly its ester or amide derivatives and said compound
FR2355506A1 (en) * 1976-06-25 1978-01-20 Azuma Ichiro IMMUNOTHERAPY ADJUVANT CONTAINING GLYCOLIPID AS ACTIVE INGREDIENT AND PROCESS FOR PREPARATION
US4154821A (en) * 1977-01-27 1979-05-15 Roussel Uclaf Novel glycoproteins
US4157278A (en) * 1977-03-22 1979-06-05 Glaxo Laboratories Limited Immunostimulatory agents
US4724144A (en) * 1984-02-17 1988-02-09 University College London Immuno-therapeutic composition of killed cells from mycobacterium vaccae
US4726947A (en) * 1978-03-10 1988-02-23 Matsui Toatsu Chemicals, Inc. Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
WO1989000860A1 (en) * 1987-08-05 1989-02-09 Biotech Connections, Inc. Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52116416A (en) * 1976-03-10 1977-09-29 Anvar 22*22acetamidee22dioxyy33oodd glucopyranosyl**ddpropionyllllceryll ddisoglutamine or glutamic acid or adjuvants composed of mainly its ester or amide derivatives and said compound
FR2355506A1 (en) * 1976-06-25 1978-01-20 Azuma Ichiro IMMUNOTHERAPY ADJUVANT CONTAINING GLYCOLIPID AS ACTIVE INGREDIENT AND PROCESS FOR PREPARATION
US4154821A (en) * 1977-01-27 1979-05-15 Roussel Uclaf Novel glycoproteins
US4157278A (en) * 1977-03-22 1979-06-05 Glaxo Laboratories Limited Immunostimulatory agents
US4726947A (en) * 1978-03-10 1988-02-23 Matsui Toatsu Chemicals, Inc. Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
US4724144A (en) * 1984-02-17 1988-02-09 University College London Immuno-therapeutic composition of killed cells from mycobacterium vaccae
WO1989000860A1 (en) * 1987-08-05 1989-02-09 Biotech Connections, Inc. Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli
US4877613A (en) * 1987-08-05 1989-10-31 Biotech Connections, Inc. Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli

Similar Documents

Publication Publication Date Title
Nickerson IV. MOLECULAR BASES OF FORM IN YEASTS
Krause et al. Studies on the chemical structure of the streptococcal cell wall: I. The identification of a mucopeptide in the cell walls of groups A and A-variant streptococci
Wessels et al. Chemical and morphological characterization of the hyphal wall surface of the basidiomycete Schizophyllum commune
Perkins et al. The products of the partial acid hydrolysis of the mucopeptide from cell walls of Micrococcus lysodeikticus
White et al. Peptidoglycan of Myxococcus xanthus: structure and relation to morphogenesis
Roberton et al. In vitro utilization of mucin by Bacteroides fragilis
Slade Extraction of cell-wall polysaccharide antigen from streptococci
Nomura et al. Nature of the primary action of the autolysin of Bacillus subtilis
GB1426042A (en) water-soluble immunological adjuvants
JPS6485925A (en) B group ii type streptococci idiosyncratic polysaccharide antigen
Mulder et al. Polysaccharides, lipids and poly‐β‐hydroxybutyrate in microorganisms
Suzuki et al. Studies on the antigenic activities of yeasts II. Isolation and inhibition assay of the oligosaccharides from acetolysate of mannan of Candida albicans
Slock et al. Polysaccharide that may serve as a carbon and energy storage compound for sporulation in Bacillus cereus
Ortiz et al. An exo-β-acetylglucosaminidase from Bacillus subtilis B: Extraction and purification
SAKAGUCHI et al. Studies on the toxin production of Clostridium botulinum type E I. A strain of genus Clostridium having the action to promote type E botulinal toxin production in a mixed culture
Langston et al. Motile enterococci (Streptococcus faecium var. mobilis var. n.) isolated from grass silage
US3189529A (en) High-activity lipase and method of preparation thereof
Hobson et al. Some serological and chemical studies on materials extracted from an amylolytic streptococcus from the rumen of the sheep
Strange Cell wall lysis and the release of peptides in Bacillus species
NO138411B (en) PROCEDURE FOR THE PREPARATION OF AN ENZYME DESIGNATED AS CARIOGENANASE
Ballesta et al. Resistance of Zygorhynchus species to lysis
GB1567106A (en) Microbial fractions
ABOU‐ZEID et al. Structure of the wall polysaccharide isolated from a group of corynebacteria
Richmond Properties of a lytic enzyme produced by a strain of Bacillus subtilis
Azuma et al. Cell wall of Mycobacterium lepraemurium strain Hawaii

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee